Skip to main content

STVN · Stevanato Group S.p.A.

Track STVN — free
$15.65 -0.28 (-1.76%) At close · Nov 20
Market Cap
$4.27B
Shares
273.13M
Volume · Nov 20 752.33K Avg daily vol (3M) 650.64K

Price & Indicators

 

Key stats

Close
$15.65
Fri 20 Nov
Open
$15.90
Fri 20 Nov
Average volume, 30 days
1.0M
shares a session
Short interest
886K
0.3% of shares · 2.1 days to cover
Day range
$15.35$16.15
Open $15.90 Close $15.65
52-week closing range
$13.21$23.43
Close $15.65 33.2% under the high
Short volume, last session
60%
Last earnings
Nov 3, 2026
Price history
Jul 2021 to Nov 2026

Up next

Mar 3, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Investor event
Expects low single-digit 2027 growth after GLP-1 client demand drop

Stevanato Group expects a temporary headwind in 2027 as one of its two GLP-1 originator clients faces lower syringe demand, so it set a safe floor of low single-digit growth. The company is backfilling excess capacity with other biologic customers and expects margin expansion and a step up in free cash flow in fiscal 2027. Detailed guidance will come in March.

5 source passages
2027, there will be a temporary headwind because one of the two originators is facing some temporary headwind on demand We want to set a safe floor in the low single-digit growth. GLP-1 is an even more attractive tailwind. we do expect still to expand margins and have a step up in free cash flow generation in fiscal 2027 However, we'll provide detailed guidance in March. Open the document at this passage
Nov 12
Current report 6-K
Third-quarter revenue rose 8%; GLP1 headwind moderates 2027 growth

Stevanato Group S.p.A. reported third-quarter 2026 revenue growth of 8% to €326.1 million, while adjusted EBITDA margin rose 150 basis points to 27.2%. Full-year guidance was reiterated, but lower GLP1 volumes are expected to temporarily moderate 2027 growth to low single digits.

6 source passages
In the third quarter of 2026, revenue grew 8% to €326.1 million, both on a reported basis and organically. Adjusted EBITDA grew 14% to €88.8 million and adjusted EBITDA margin increased 150 basis points to 27.2% in the third quarter of 2026. We are reiterating our full year guidance and still expect revenue in the range of €1.260 billion to €1.280 billion, adjusted EBITDA between €335 million and €345.2 million, and adjusted diluted EPS is still expected to range between €0.60 and €0.62 for the fiscal year. In the short term, the adjustments to anticipated GLP1 volume will temporarily moderate growth in 2027. Based on what we know today, we believe we can still grow low-single-digits in 2027 driven by favorable secular trends across the broader biologics area. Welcome and thank you for joining the Stevanato Group Third Quarter Financial Results Conference Call. Open the document at this passage
Nov 3
Current report 6-K
Nine-month revenue rises while net profit edges higher

Stevanato Group S.p.A. reported revenue of 901,640 thousand euros for the nine months ended September 30, 2026, versus 839,800 thousand euros, while net profit was 92,821 thousand euros versus 92,279 thousand euros.

Read from the first part of this long document
3 source passages
Stevanato Group S.p.A. Interim consolidated income statement for the three and nine months ended September 30, 2026 and 2025 Revenue | 9 | | 326,063 | | | 303,167 | | | 901,640 | | | 839,800 Net Profit | | | 41,838 | | | 36,062 | | | 92,821 | | | 92,279 Open the document at this passage
Nov 3
Current report 6-K
Q3 revenue grows 8% as adjusted EBITDA margin expands to 27.2%

Stevanato Group reported Q3 2026 revenue growth of 8%, driven by BDS organic growth of 11%, while adjusted EBITDA rose 14% to €88.8M and margin expanded to 27.2%. It expects lower GLP-1 volumes than previously anticipated for FY27.

4 source passages
Stevanato Group Q3 2026 Financial Results In Q3 2026, revenue grew 8%, driven by 11% organic* growth in the BDS Segment, that offset 12% decline in the Engineering Segment Adjusted EBITDA* increased 14% to €88.8M; adjusted EBITDA margin* increased 150 bps to 27.2% Within our GLP-1 portfolio, we now expect lower volumes than previously anticipated for FY27 Open the document at this passage
Nov 3
Current report 6-K
Third-quarter revenue rose 8%; full-year guidance maintained

Stevanato Group reported third-quarter 2026 revenue of €326.1 million, up 8%, and adjusted EBITDA of €88.8 million. The company maintained fiscal 2026 guidance of €1.260 billion to €1.280 billion in revenue.

4 source passages
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 For the third quarter of 2026, revenue increased 8% to €326.1 million, and 8% organically, compared to the same period last year. For the third quarter of 2026, adjusted EBITDA increased 14% to €88.8 million, and adjusted EBITDA margin improved 150 basis points to 27.2%, compared with the same period last year. The Company is maintaining its full-year 2026 guidance and still expects revenue to range between €1.260 billion and €1.280 billion, adjusted EBITDA of €335.0 million to €345.2 million, and adjusted diluted EPS of €0.60 to €0.62. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.45B
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+7.6%
Year over year
Operating margin
16.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
7.9%
Trailing 12 months
Net cash
−$399.34M
Latest balance sheet
Dividend yield
0.4%
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
-26.0%
Trailing year
Short interest
0.3%
Latest settlement · 2.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg −16%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 24%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −20%
trailing
6-month return −17%
trailing
YTD return −22%
this year
Relative strength −8%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $19 › 200d $18 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +27 funds added
Insider flow Accumulating
Net +$307.7K over 90 days · 33% sells
Short interest Falling
0.32% of shares out · ▼ -8.2% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
132 holders — mid 3-yr range
Squeeze score 43
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 55%
annualized · 1-yr
Max drawdown −44%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 3, 2026
full year 2026
Revenue from the engineering segment $124M – $134M
CAPEX $230M – $240M
CAPEX, net of customer contribution $215M – $225M
for the year
High-value solutions as a percentage of revenue 47% – 48%
Q4
High-value solutions mix 50%
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Tax rate · 2026 28.2%
High-value solutions as a percentage of total company revenue · fiscal 2026 47% – 48%
High-value solutions as percent of total company revenue · full year 2026 47% – 48%
Adjusted beta margin · at the center point of the guide 26.8%
Adjusted tax rate · 2026 28.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
−16% Bearish
RSI (14)
43 Neutral
MACD trend
Positive Bullish
52-week position
24% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $19 › 200d $18 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +27 funds added
Insider flow Accumulating
Net +$307.7K over 90 days · 33% sells
Short interest Falling
0.32% of shares out · ▼ -8.2% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
132 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $13 Now $16 · 24% Range high $23
vs 200-day avg -13% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
STVN
Stevanato Group S.p.A.
this stock
$4.27B -22.2% — — 0.3%
ISRG
Intuitive Surgical Inc
$138.33B -29.5% +20.5% 48.4 2.0%
BDX
Becton Dickinson & Co
$57.96B — +8.2% 94.2 3.0%
MDLN
Medline Inc.
$48.72B -11.8% +11.5% — 2.9%
ALC
Alcon Inc
$35.70B -5.7% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
132
% held
16.8%
Net QoQ
+1.2M sh
Top holder
NEUBERGER BERMAN GROUP LLC
Held Float
View
Held by Funds
Fund positions
22
View
Short & Settlement
Short Interest Falling
Shares short
886.3K
Days to cover
2.1d
Change
-79.7K sh
View
Short Volume
Short vol %
60%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
17.9K
Value
$344.1K
As of
Oct 16, 2026
View
Off-Exchange
Off-exchange %
39.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$307.7K
Buyers / Sellers
2 / 1
Buyers Sellers
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
25

Stevanato Group expects a temporary headwind in 2027 as one of its two GLP-1 originator clients faces lower syringe demand, so it set a safe floor of low single-digit growth. The company is backfilling excess capacity with other biologic customers and expects margin expansion and a step up in free cash flow in fiscal 2027. Detailed guidance will come in March.

View
Proposed Sales
Value
$276.3K
Shares
13.6K
Filed
Sep 14, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Stevanato Group to Participate in…
Published
Nov 16, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
STVN -1.0% -19.7% -16.7% -19.3% -22.2%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +7.6% -10.5% -7.5% -10.5% -23.4%

Capital returns

Latest dividend
$0.062 / share · ex Jun 11, 2026
Raised 6.9%
Paid (TTM)
$0.062 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1849853 CUSIP T9224W109 13F (30d) 138 filings 117 filers Visit website Investor relations